Document is current
Any future updates will be listed below
-
Authors
Lee, Karla A.
Thomas, Andrew Maltez
Bolte, Laura A. http://orcid.org/0000-0001-6036-0831
Björk, Johannes R.
de Ruijter, Laura Kist http://orcid.org/0000-0002-2639-3784
Armanini, Federica
Asnicar, Francesco http://orcid.org/0000-0003-3732-1468
Blanco-Miguez, Aitor http://orcid.org/0000-0001-7386-5572
Board, Ruth
Calbet-Llopart, Neus http://orcid.org/0000-0003-0443-3025
Derosa, Lisa
Dhomen, Nathalie
Brooks, Kelly
Harland, Mark
Harries, Mark
Leeming, Emily R.
Lorigan, Paul http://orcid.org/0000-0002-8875-2164
Manghi, Paolo http://orcid.org/0000-0003-0846-6529
Marais, Richard
Newton-Bishop, Julia
Nezi, Luigi http://orcid.org/0000-0002-4670-7656
Pinto, Federica
Potrony, Miriam http://orcid.org/0000-0003-2766-0765
Puig, Susana http://orcid.org/0000-0003-1337-9745
Serra-Bellver, Patricio
Shaw, Heather M.
Tamburini, Sabrina
Valpione, Sara
Vijay, Amrita
Waldron, Levi
Zitvogel, Laurence http://orcid.org/0000-0003-1596-0998
Zolfo, Moreno
de Vries, Elisabeth G. E. http://orcid.org/0000-0002-8949-7425
Nathan, Paul
Fehrmann, Rudolf S. N. http://orcid.org/0000-0002-7516-315X
Bataille, Véronique
Hospers, Geke A. P.
Spector, Tim D. http://orcid.org/0000-0002-9795-0365
Weersma, Rinse K. http://orcid.org/0000-0001-7928-7371
Segata, Nicola http://orcid.org/0000-0002-1583-5794
- License Information
-
More Information
Article History
Received: 24 March 2021
Accepted: 13 January 2022
First Online: 28 February 2022
Competing interests
: R.K.W. acted as a consultant for Takeda; received unrestricted research grants from Takeda, Johnson & Johnson, Tramedico and Ferring; and received speaker fees from MSD, AbbVie and Janssen Pharmaceuticals. E.R.L. is a consultant for ZOE Global. E.G.E.d.V. reports an advisory role at Daiichi Sankyo, NSABP and Sanofi (paid to University Medical Center Groningen) and research funding from Amgen, AstraZeneca, Bayer, Chugai Pharma, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier and Synthon (paid to University Medical Center Groningen). S.P. received speaker fees from Almirall, BMS, ISDIN, La Roche Posay, Leo Pharma, Regeneron, Roche and Sanofi; acted as advisory board member of Almirall, ISDIN, La Roche Posay, Pfizer, Roche, Regeneron, Sanofi and Sun Pharma; and received research funding from Abbie, AMGEN, ISDIN, La Roche Posay, Leo Pharma and Novartis. R.B. has received honoraria from, and sits on advisory boards of, Novartis, BMS and MSD. All other authors declare no competing interests.
